Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
UNIVERSITE CLAUDE BERNARD - LYON 1 has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner in 1 distinct art unit. SEAN E AEDER serves as the busiest examiner for the portfolio with 1 pending office action. The current prosecution activity is limited to this single examiner, reflecting a narrow scope of active patent examination for the organization.
The 1 pending office action represents the total volume of current interaction with the patent office. Since the prosecution is situated within the Biotechnology & Pharmaceuticals technology area, the company's legal focus remains specialized. SEAN E AEDER, as the busiest examiner with 1 pending office action, is the sole point of contact for the company's active intellectual property matters. This 1 distinct examiner and 1 distinct art unit arrangement simplifies the management of the current portfolio, as there are no competing deadlines or varying examiner styles to navigate across the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
| COONEY, JOHN M | 1 | 62.9% | +21.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274568 | NOVEL SIALOSIDES AND THEIR USE IN THERAPY | CRAIGO, BAHAR ALAWI | — |
| 18032044 | BIOBASED MATERIAL AND METHOD FOR PREPARING SAME | COONEY, JOHN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274568 | NOVEL SIALOSIDES AND THEIR USE IN THERAPY | CRAIGO, BAHAR ALAWI | — |
| 18032044 | BIOBASED MATERIAL AND METHOD FOR PREPARING SAME | COONEY, JOHN M | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1765 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274568 | NOVEL SIALOSIDES AND THEIR USE IN THERAPY | CRAIGO, BAHAR ALAWI | 1699 | §103§112 | Final Rejection | — | Pending | Jul 27, 2023 |
| 18032044 | BIOBASED MATERIAL AND METHOD FOR PREPARING SAME | COONEY, JOHN M | 1765 | §102§103§112 | Final Rejection | — | Pending | Apr 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE CLAUDE BERNARD - LYON 1 has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bahar Alawi Craigo has the most, with 1 of UNIVERSITE CLAUDE BERNARD - LYON 1's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
